Melbourne, Australia; 25 May 2016: Starpharma Holdings Ltd (ASX: SPL, OTCQX: SPHRY) today announced that Starpharma’s DEP™ cabazitaxel eliminated neutropenia typical of cabazitaxel (Jevtana^®) in a preclinical study. 

The Conversation noted Dual Protect™ anti-viral condoms, which are coated with Starpharma’s VivaGel®, provide an extra level of protection over regular condoms for Australia athletes when they are at the Olympics in Rio. 

Go to the article (external link)

Starpharma is presenting today at The CEO Session Series event in Sydney.

Starpharma and Ansell today proudly announce that the Australian Olympic team will be provided with antiviral Dual Protect™ VivaGel^® condoms for the upcoming Olympic Games in Rio de Janeiro.

Starpharma announced today that the VivaGel^® active, astodrimer sodium (SPL7013), has been shown to have potent antiviral activity against the Zika virus in laboratory studies. The studies showed near complete antiviral protection at SPL7013 concentrations significantly below that used in the VivaGel^® condom.